PMCH (Pacific Medical College & Hospital) | ClinicalTrials HQ

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.	Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervical squamous cell carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal adenocarcinoma, esophageal cancer, esophageal disorder, esophageal squamous cell carcinoma, estrogen-receptor positive breast cancer, female reproductive system disorder, female reproductive system neoplasm, gastroesophageal cancer, gonadal disorder, head and neck squamous cell carcinoma, hepatocellular carcinoma, kidney cancer, kidney disorder, liver disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreatic adenocarcinoma, primitive neuroectodermal tumor, prostate cancer, prostate disorder, renal cell carcinoma, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder	Active, not recruiting	Phase 1	2025-11-28		NCT03983954